-
公开(公告)号：EP0330700B1
公开(公告)日：1993-12-22
申请号：EP88907361.5
申请日：1988-08-18
申请人： SAGAMI CHEMICAL RESEARCH CENTER , CENTRAL GLASS COMPANY, LIMITED , HODOGAYA CHEMICAL COMPANY, LIMITED , NIPPON SODA CO., LTD. , NISSAN CHEMICAL INDUSTRIES LTD. , TOSOH CORPORATION
IPC分类号： C12N9/72 , C12N15/00 , C12N1/20 , C12P21/02 , A61K37/465
CPC分类号： C12N9/6462 , C12Y304/21073
摘要： A human prourokinase-like polypeptide having an amino acid sequence represented by the following formula: (Met).Ser1-X156.Y157.Z158- (wherein Met represents an optionally existing methionine, Ser represents serine present at 1-position of the N-terminal, X represents arginine or other amino acid present at 156-position, Y represents proline, glycine, alanine or valine present at 157-position, Z represents lysine or arginine present at 158-position, and the solid line represents the same amino acid sequence as that of corresponding part of natural human prourokinase or human urokinase-like polypeptide wherein lysine at 135-position is replaced by other amino acid than basic amino acids) or having an amino acid sequence substantially the same as this is disclosed. In addition, a DNA segment which codes the above-described polypeptide; a plasmid containing said DNA segment; E. coli transformed by said plasmid; a process for preparing said polypeptide by culturing said E. coli; a medicine containing said polypeptide; use of said polypeptide for prophylaxis or treatment for formation of thrombus; and use of said polypeptide for preparing the medicine for the above purpose are also disclosed.
-
公开(公告)号：EP0210279B1
公开(公告)日：1991-08-14
申请号：EP86900852.4
申请日：1986-01-24
申请人： SAGAMI CHEMICAL RESEARCH CENTER , CENTRAL GLASS COMPANY, LIMITED , HODOGAYA CHEMICAL COMPANY, LIMITED , NIPPON SODA CO., LTD. , NISSAN CHEMICAL INDUSTRIES LTD. , Tosoh Corporation
发明人： MIYAKE, Toshio , HIBINO, Yasuo , KOBAYASHI, Yoichi , WATABE, Ken , OMORI, Muneki , MIKI, Tetsuzo , YOKOYAMA, Midori , MATSUMOTO, Reiko , WATANABE, Kazuo , NUMAO, Naganori
CPC分类号： C12N9/6462 , C12N15/73 , C12Y304/21073
摘要： Stabilized human prourokinase-like polypeptides wherein the 135th lysine from the N-terminal of human prourokinase is substituted by an amino acid other than basic amino acids, the 157th phenylalanine is substituted by an acidic amino acid, or both of the amino acids are substituted as described above; DNA segment which codes said polypeptides; plasmid which contains said DNA segment; E. coli transformed by said plasmid; and a process for preparing said polypeptide by using said E. coli. The polypeptides are stable against proteases such as plasmin, thrombin, trypsin, etc., thus being easily purified and collected in a pure form. When applied to a living body, the polypeptides are expected to provide a persistent fibrinolytic activity.
-
公开(公告)号：EP0210279A1
公开(公告)日：1987-02-04
申请号：EP86900852.4
申请日：1986-01-24
申请人： SAGAMI CHEMICAL RESEARCH CENTER , CENTRAL GLASS COMPANY, LIMITED , HODOGAYA CHEMICAL COMPANY, LIMITED , NIPPON SODA CO., LTD. , NISSAN CHEMICAL INDUSTRIES LTD. , Tosoh Corporation
发明人： MIYAKE, Toshio , HIBINO, Yasuo , KOBAYASHI, Yoichi , WATABE, Ken , OMORI, Muneki , MIKI, Tetsuzo , YOKOYAMA, Midori , MATSUMOTO, Reiko , WATANABE, Kazuo , NUMAO, Naganori
CPC分类号： C12N9/6462 , C12N15/73 , C12Y304/21073
摘要： Stabilized human prourokinase-like polypeptides wherein the 135th lysine from the N-terminal of human prourokinase is substituted by an amino acid other than basic amino acids, the 157th phenylalanine is substituted by an acidic amino acid, or both of the amino acids are substituted as described above: DNA segment which codes said polypeptides; plasmid which contains said DNA sigment; E. coli transformed by said plasmid; and a process for preparing said polypeptide by using said E.coli. The polypeptides are stable against proteases such as plasmin, thrombin, trypsin. etc. thus being easily purified and collected in a pure form. When applied to a living body, the polypeptides are expected to provide a persistent fibrinolytic activity.
摘要翻译： 稳定的人类原尿激酶样多肽，其中人原尿激酶N末端的第135位赖氨酸被除碱性氨基酸以外的氨基酸取代，第157位苯丙氨酸被酸性氨基酸取代，或两者均被取代为 编码所述多肽的DNA片段; 含有所述DNA指征的质粒; 由所述质粒转化的大肠杆菌; 以及通过使用所述大肠杆菌制备所述多肽的方法。 多肽对蛋白酶如纤溶酶，凝血酶，胰蛋白酶是稳定的。 因此容易地以纯的形式纯化和收集。 当应用于活体时，期望多肽提供持久的纤维蛋白溶解活性。
-
公开(公告)号：EP0330700A1
公开(公告)日：1989-09-06
申请号：EP88907361.5
申请日：1988-08-18
申请人： SAGAMI CHEMICAL RESEARCH CENTER , CENTRAL GLASS COMPANY, LIMITED , HODOGAYA CHEMICAL COMPANY, LIMITED , NIPPON SODA CO., LTD. , NISSAN CHEMICAL INDUSTRIES LTD. , TOSOH CORPORATION
IPC分类号： C12N9/72 , C12N15/00 , C12N1/20 , C12P21/02 , A61K37/465
CPC分类号： C12N9/6462 , C12Y304/21073
摘要： A human prourokinase-like polypeptide having an amino acid sequence represented by the following formula: (Met).Ser¹-X¹⁵⁶.Y¹⁵⁷.Z¹⁵⁸- (wherein Met represents an optionally existing methionine, Ser represents serine present at 1-position of the N-terminal, X represents arginine or other amino acid present at 156-position, Y represents proline, glycine, alanine or valine present at 157-position, Z represents lysine or arginine present at 158-position, and the solid line represents the same amino acid sequence as that of corresponding part of natural human prourokinase or human urokinase-like polypeptide wherein lysine at 135-position is replaced by other amino acid than basic amino acids) or having an amino acid sequence substantially the same as this is disclosed. In addition, a DNA segment which codes the above-described polypeptide; a plasmid containing said DNA segment; E. coli transformed by said plasmid; a process for preparing said polypeptide by culturing said E. coli ; a medicine containing said polypeptide; use of said polypeptide for prophylaxis or treatment for formation of thrombus; and use of said polypeptide for preparing the medicine for the above purpose are also disclosed.
摘要翻译： 具有由下式表示的氨基酸序列的人类原尿激酶样多肽：（Met）.Ser 1 -X 1 <5> 6 .Y 1 <5> 7。 （其中Met表示任意存在的甲硫氨酸，Ser表示N-末端1位存在的丝氨酸，X表示156位存在的精氨酸或其他氨基酸，Y表示脯氨酸，甘氨酸 ，存在于157位的丙氨酸或缬氨酸，Z表示存在于158位的赖氨酸或精氨酸，实线表示与天然人尿细胞激肽或人尿激酶样多肽的相应部分相同的氨基酸序列，其中赖氨酸为135 - 位置被除了碱性氨基酸以外的其它氨基酸替代）或具有与所公开的基本相同的氨基酸序列。 此外，编码上述多肽的DNA区段; 含有所述DNA片段的质粒; 由所述质粒转化的大肠杆菌; 通过培养所述大肠杆菌来制备所述多肽的方法; 含有所述多肽的药物; 使用所述多肽预防或治疗形成血栓; 并且还公开了用于制备用于上述目的的药物的所述多肽的用途。
-
公开(公告)号：EP1352964A1
公开(公告)日：2003-10-15
申请号：EP00985832.5
申请日：2000-12-22
摘要： An industrially advantageous process for producing a substance wherein the production speed of a reaction product in a reaction with the use of a microbial catalyst can be maintained at a constant level over a long period of time. In a reaction with the use of a microbial catalyst (for example, resting cells of an arthrobacter capable of converting a-hydroxynitriles into the corresponding a-hydroxy acid amides or a-hydroxy acid ammonium salts), the substance is produced at a constant speed by adding the substrate at a constant speed, regulating the concentration of the microbial catalyst in the liquid reaction mixture at a constant level and controlling the temperature so as to rise the reaction temperature at the point that the enzymatic activity of the microbial catalyst is lowered in the course of the reaction so as to maintain the reaction speed at a constant level.
摘要翻译： 的制造worin与使用的微生物催化剂的反应的反应产物的生产速度的物质的工业上有利的方法可以保持在恒定的电平在一段长的时间。 与使用的微生物催化剂的反应（例如，休息能够将一个羟基腈成相应的α-羟基酸的酰胺或α-羟基酸的铵盐的节杆菌的细胞），该物质被以恒定的速度产生 通过以恒定的速度添加底物，在恒定水平调节在液体反应混合物中的微生物催化剂的浓度和控制温度，以便上升，反应温度在点做了微生物催化剂的酶活性以降低 在反应的过程中，从而保持反应速度在恒定的水平。
-
-
-
-
搜索结果
5 条记录 (耗时 0.031 秒)
